ALVAL.PA

Consumer Defensive Packaged Foods

Valbiotis SA

€0.64

-0.01 -2.00% today

Price History

Not enough data

Key Stats

Market Cap

22.61M

Avg Volume

85,979

EPS

-€0.47

52W High

€1.30

52W Low

€0.54

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-7.96

P/B Ratio

2.17

P/S Ratio

24.98

EV/EBITDA

-1.25

EV/Revenue

12.69

Margins

Gross Margin (128.8%)

Operating Margin (844.1%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

305.7%

Return on Equity

(108.7%)

Return on Assets

(34.9%)

Liquidity & Leverage

Current Ratio

2.85

Quick Ratio

2.22

Debt / Equity

0.73

Total Cash

8.68M

Total Debt

5.09M

About

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.